Phase 2 Multiple Sclerosis Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with secondary progressive multiple sclerosis (a form of MS where disability gradually worsens over time), confirmed using a specific set of diagnostic standards that measure how much disability has progressed and over what period of time (confirm with trial site for full details)
- People whose MS-related disability level, measured on a standard scale used by neurologists, is rated at 6.5 or above at the start of the trial
Who may not be able to join:
- People who have previously taken MS-modifying medications other than a drug called rituximab
- People who have had an MS relapse (a sudden worsening of symptoms) within the 3 months before joining the trial
- People who have a known allergy or medical reason why rituximab would not be safe for them
- People who have another neurological condition (a condition affecting the brain or nervous system) that could affect their thinking, memory, or hand and arm function
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Maha Atef Zaki, MD Neurology, Department of Neurology, Faculty of Medicine, Cairo University
Phone: 00201005393868
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The effect of rituximab on cognitive functions assessed by The Symbol Digit Modalities Test; The effect of rituximab on cognitive functions assessed by The Brief Visuospatial Memory Test-Revised; The effect of rituximab on cognitive functions assessed by The California Verbal Learning Test-II; The effect of rituximab on hand functions assessed by The Nine-Hole Peg Test
Can't join this trial?
Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.